Valbiotis SA
PAR:ALVAL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its Industry Average (19.9), the stock would be worth €-9.23 (1 097% downside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -2 | €0.93 |
0%
|
| Industry Average | 19.9 | €-9.23 |
-1 097%
|
| Country Average | 15.8 | €-7.34 |
-893%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| FR |
|
Valbiotis SA
PAR:ALVAL
|
21.9m EUR | -2 | -2.3 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -211 184.9 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
360.5B USD | 24.3 | 90 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
182.2B USD | 28.2 | 24.3 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
159.9B USD | 18.5 | 19.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -531.1 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
107.5B USD | 31.7 | 27.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
72.5B USD | 14.1 | 16.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
40.6B EUR | 142.2 | 37.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -64.3 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60.6B AUD | 20.5 | 29.4 |
Market Distribution
| Min | 0.9 |
| 30th Percentile | 10.4 |
| Median | 15.8 |
| 70th Percentile | 25.1 |
| Max | 2 752.4 |
Other Multiples
Valbiotis SA
Glance View
Valbiotis SA develops products and candidate drugs designed to prevent metabolic diseases. The company is headquartered in Perigny, Nouvelle-Aquitaine. The company went IPO on 2017-06-07. The firm specializes in developing nutrition solutions designed to prevent cardiometabolic diseases and provide nutritional support for patients. The company seeks to develop solutions designed to prevent type 2 diabetes, NASH, (non-alcoholic steatohepatitis) and obesity and to offer nutritional support. The firm prevents disease by developing products that reduce the risk factors of irreversible chronic diseases. The company provides patient support through new-generation medical nutrition solutions containing patented substances with clinically proven effects. Its products are plant-based and undergo strict scientific and clinical tests in collaboration with academic research centers.
